文献速递膀胱癌与上尿路尿路上皮癌

氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描对肌层浸润性膀胱癌的分期:一项全国性人群基础研究

Staging fluorodeoxyglucose positron emission tomography/computed tomography for muscle-invasive bladder cancer: a nationwide population-based study.
PubMed 文献 · BJU Int · 2023-06-15

该研究基于荷兰2017年11月至2019年10月新诊断的2731例无远处转移的肌层浸润性膀胱癌患者,比较仅CT与CT联合FDG-PET/CT分期对淋巴结状态及治疗的影响。结果显示,CT联合FDG-PET/CT组临床淋巴结阳性(cN+)比例更高(35.8% vs 10.6%),且在CT分期为cN0的患者中,FDG-PET/CT使21.9%升期为cN+。接受FDG-PET/CT分期的患者更常接受术前化疗,且cN+患者行根治性膀胱切除术后病理N分期一致性更高(50.0% vs 39.3%)。

要点

  • 在肌层浸润性膀胱癌患者中,CT联合FDG-PET/CT分期者临床淋巴结阳性比例高于仅CT分期者(35.8% vs 10.6%)。
  • CT分期为cN0的患者中,FDG-PET/CT使21.9%升期为cN+。
  • FDG-PET/CT分期组cN+患者根治性膀胱切除术后病理N分期一致性为50.0%,仅CT组为39.3%。

核心结论

  • 接受FDG-PET/CT分期的肌层浸润性膀胱癌患者无论临床T分期如何,更常被判定为淋巴结阳性;FDG-PET/CT使约五分之一的患者临床淋巴结升期,额外影像发现可能影响后续治疗策略。

研究设计与样本

  • 全国性人群基础队列研究,纳入荷兰2017年11月至2019年10月新诊断的无远处转移征象的肌层浸润性膀胱癌患者2731例。
  • 从队列中选择接受仅CT或CT联合FDG-PET/CT进行 pretreatment 分期的患者,按影像 modality 分组描述患者分布、疾病特征、影像发现、淋巴结状态(cN0 vs cN+)和治疗。

主要发现

  • 2731例患者中,1888例(69.1%)仅接受CT,606例(22.2%)接受CT联合FDG-PET/CT,237例(8.6%)未接受CT。
  • 仅CT组中200/1888例(10.6%)为cN+,CT联合FDG-PET/CT组中217/606例(35.8%)为cN+;分层分析显示该差异见于cT2期以及cT3/4期肌层浸润性膀胱癌患者。
  • 接受两种影像检查且CT分期为cN0的患者中,109/498例(21.9%)基于FDG-PET/CT升期为cN+。
  • 根治性膀胱切除术是两组中最常见的治疗;术前化疗在cN+疾病和FDG-PET/CT分期患者中更常应用。
  • upfront 根治性膀胱切除术后病理N分期一致性在CT联合FDG-PET/CT分期为cN+的患者中为50.0% pN+,高于仅CT分期为cN+患者的39.3%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To provide insight into the use and staging information on lymph-node involvement added by fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in patients with muscle-invasive bladder cancer (MIBC), based on a nationwide population-based cohort study. PATIENTS AND METHODS: We analysed a nationwide cohort of patients with MIBC without signs of distant metastases, newly diagnosed in the Netherlands between November 2017 and October 2019. From this cohort, we selected patients who underwent pre-treatment staging with CT only or CT and FDG-PET/CT. The distribution of patients, disease characteristics, imaging findings, nodal status (clinical nodal stage cN0 vs cN+) and treatment were described for each imaging modality group (CT only vs CT and FDG-PET/CT). RESULTS: We identified 2731 patients with MIBC: 1888 (69.1%) underwent CT only; 606 (22.2%) underwent CT and FDG-PET/CT, 237 (8.6%) underwent no CT. Of the patients who underwent CT only, 200/1888 (10.6%) were staged as cN+, vs 217/606 (35.8%) who underwent CT and FDG-PET/CT. Stratified analysis showed that this difference was found in patients with clinical tumour stage (cT)2 as well as cT3/4 MIBC. Of patients who underwent both imaging modalities and were staged with CT as cN0, 109/498 (21.9%) were upstaged to cN+ based on FDG-PET/CT. Radical cystectomy (RC) was the most common treatment within both imaging groups. Preoperative chemotherapy was more frequently applied in cN+ disease and in FDG-PET/CT-staged patients. Concordance of pathological N stage after upfront RC was higher among patients staged as cN+ with CT and FDG-PET/CT (50.0% pN+) than those staged as cN+ with only CT (39.3%). CONCLUSION: Patients with MIBC who underwent pre-treatment staging with FDG-PET/CT were more often staged as lymph node positive, regardless of cT stage. In patients with MIBC who underwent CT and FDG-PET/CT, FDG-PET/CT led to clinical nodal upstaging in approximately one-fifth. Additional imaging findings may influence subsequent treatment strategies.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Richters A, van Ginkel N, Meijer RP, et al. Staging fluorodeoxyglucose positron emission tomography/computed tomography for muscle-invasive bladder cancer: a nationwide population-based study. BJU Int. 2023. PMID: 37246479. doi:10.1111/bju.16091

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。